Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
NEW DEADLINE
Due to the coronavirus pneumonia epidemic, the call submission deadline for CE-BIOTEC-08-2020 is extended further until Friday 19 June 2020 at 17:00:00 Brussels (local time)
The deadline set by the funding counterpart in China, the Natural National Science Foundation of China (NSFC), is identical.
More detailed information can be found here
Source: Funding and Tender Portal
2023-10-09
|
5 months ago |
Last few days to respond to survey: help us further improve NCP Flanders services |
2023-09-27
|
6 months ago |
NCP Flanders survey still open until 13 October |
2023-08-21
|
7 months ago |
NCP Flanders survey: looking for your feedback |
2023-06-08
|
9 months ago |
Industry 5.0 Award 2023- open for submission |
2022-03-24
|
2 years ago |
HosmartAI Open Call - €200k fund for Startups/SMEs developing AI-powered technology... |
2021-10-19
|
2 years ago |
Pharaon Open Call for (micro) SMEs - Making smart and active living for Europe's age... |
2021-10-05
|
2 years ago |
New NCP Flanders Advisor - Health Cluster |
2021-03-29
|
3 years ago |
HEI Initiative: Innovation Capacity Building for Higher Education: Pilot Call for Pro... |
We offer news and event updates, covering all domains and topics of Horizon 2020 & Horizon Europe.
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.